Impact of different dose reduction criteria for anti-Xa direct oral anticoagulants on bleeding complications: A single center observational study.
anti‐Xa direct oral anticoagulants
atrial fibrillation
bleeding complications
dose reduction criteria
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
01
10
2021
revised:
14
03
2022
accepted:
28
03
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Each direct oral anticoagulant (DOAC) has different dose reduction criteria. Here, we evaluated the differences in the doses of three anti-Xa DOACs and clinical events based on the dose reduction criteria in patients with atrial fibrillation (AF). Consecutive AF patients prescribed with anti-Xa DOACs [rivaroxaban (Riva), apixaban (Apix), and edoxaban (Edox)] between April 2011 and May 2016 were retrospectively evaluated. The incidences of thromboembolic and bleeding events were evaluated by the end of December 2020, focusing on the dose proportion. A total of 786 patients (72 ± 10 years old, 66.9% male) were enrolled in this study [Riva ( The patients with a standard dose of Apix had a higher incidence of minor bleeding events than the other dosages. A reduced dose of apixaban was not prone to being chosen because of the dose reduction criteria, which may have been associated with a higher minor bleeding rate in patients with Apix.
Sections du résumé
Background
UNASSIGNED
Each direct oral anticoagulant (DOAC) has different dose reduction criteria. Here, we evaluated the differences in the doses of three anti-Xa DOACs and clinical events based on the dose reduction criteria in patients with atrial fibrillation (AF).
Methods
UNASSIGNED
Consecutive AF patients prescribed with anti-Xa DOACs [rivaroxaban (Riva), apixaban (Apix), and edoxaban (Edox)] between April 2011 and May 2016 were retrospectively evaluated. The incidences of thromboembolic and bleeding events were evaluated by the end of December 2020, focusing on the dose proportion.
Results
UNASSIGNED
A total of 786 patients (72 ± 10 years old, 66.9% male) were enrolled in this study [Riva (
Conclusions
UNASSIGNED
The patients with a standard dose of Apix had a higher incidence of minor bleeding events than the other dosages. A reduced dose of apixaban was not prone to being chosen because of the dose reduction criteria, which may have been associated with a higher minor bleeding rate in patients with Apix.
Identifiants
pubmed: 35785369
doi: 10.1002/joa3.12716
pii: JOA312716
pmc: PMC9237315
doi:
Types de publication
Journal Article
Langues
eng
Pagination
386-394Informations de copyright
© 2022 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
HF received lecture fees from Nippon Boehringer Ingelheim and Daiichi‐Sankyo, J.O., HN, TI, TF, NI, TY, AS, and JK have no conflict of interest. SN received lecture fees from Boehringer Ingelheim, Bayer, Bristol‐Myers Squib, and Daiichi‐Sankyo. JA received research funding from Bristol Meyers Squib, Pfizer, Boehringer Ingelheim, Bayer, and Daiichi‐Sankyo and lecture fees from Sanofi, Bristol‐Meyers, Pfizer, Boehringer Ingelheim, Bayer, and Daiichi‐Sankyo.
Références
Circ J. 2018 Sep 25;82(10):2500-2509
pubmed: 30078823
J Arrhythm. 2020 Mar 24;36(3):395-405
pubmed: 32528563
PLoS One. 2018 Sep 5;13(9):e0203380
pubmed: 30183755
Am J Cardiol. 2016 Jul 15;118(2):215-21
pubmed: 27255662
Am J Med. 2010 Jul;123(7):638-645.e4
pubmed: 20609686
J Arrhythm. 2019 May 09;35(3):506-514
pubmed: 31293700
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Heart Rhythm. 2017 Apr;14(4):501-507
pubmed: 28042092
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Int J Cardiol. 2018 May 1;258:126-132
pubmed: 29429636
Heart Rhythm. 2019 Aug;16(8):e66-e93
pubmed: 30703530
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604
pubmed: 27978942
Nephron. 1976;16(1):31-41
pubmed: 1244564
BMJ. 2017 Feb 10;356:j510
pubmed: 28188243
Circ J. 2012;76(9):2104-11
pubmed: 22664783
Circ J. 2014;78(9):2166-72
pubmed: 24976391
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):415-423
pubmed: 33471125
J Arrhythm. 2017 Aug;33(4):289-296
pubmed: 28765759
J Cardiol. 2013 Apr;61(4):260-6
pubmed: 23403369
Clin Cardiol. 2020 Mar;43(3):251-259
pubmed: 31737921
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
J Cardiol. 2019 Jun;73(6):507-514
pubmed: 30737182
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
J Thromb Haemost. 2017 Jul;15(7):1322-1333
pubmed: 28407368
J Cardiol. 2019 Jul;74(1):60-66
pubmed: 30745002
Int J Cardiol. 2009 Oct 2;137(2):102-7
pubmed: 18691774
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Circ J. 2014;78(8):1997-2021
pubmed: 24965079
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325
Int Heart J. 2019 Nov 30;60(6):1321-1327
pubmed: 31735777
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607
Circulation. 2013 Jun 4;127(22):2166-76
pubmed: 23640971
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354